Know Cancer

forgot password

Randomized Phase II Trial of Two Sequential Schedules of Docetaxel and Cisplatin Followed by Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer.

Phase 2
18 Years
70 Years
Not Enrolling
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

Randomized Phase II Trial of Two Sequential Schedules of Docetaxel and Cisplatin Followed by Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer.

Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of NSCLC; Histologic subtypes
may include large cell, squamous cell, or adenocarcinoma or a generic cytological
diagnosis of NSCLC;

- Patients must have a locoregionally advanced unresectable non metastatic NSCLC Stage
IIIB (only N3 supraclavicular or T4 for pleural effusion) or Stage IV according to
the revised International Staging System;

- Patients must have at least one measurable lesion according to RECIST criteria.

- Previous radical surgery (more 30 days before study entry) is allowed but a
pathologic proof of progression of neoplastic disease must be documented;

- WHO Performance Status 0 or 1 ;

- Weight loss < 5% within the last 3 months;

- Laboratory requirements at entry

- Blood cell counts: Absolute neutrophils > 2.0 . 10^9/L; Platelets > 100 .
10^9/L; Hemoglobin > 10 g/dl

- Renal function: Serum creatinine < 1 upper normal limits (UNL). In case of limit
value of serum creatinine, the creatinine clearance should be > 60 mL/min

- Hepatic functions: Serum bilirubin < 1 x UNL; ASAT and ALAT < 2.5 x UNL;
Alkaline phosphatase < 5 x UNL (unless accompanied by extensive bone metastases)

Exclusion Criteria:

- Prior systemic chemotherapy or immunotherapy ; prior neoadjuvant or adjuvant
chemotherapy is allowed if ended at least 12 months before enrollment;

- Prior radiotherapy for NSCLC to measurable lesions. Prior radiotherapy (to < 25% of
the bone marrow) is allowed in non target lesions. At least 4 weeks must be elapsed
since the completion of the radiotherapy and the patient must have all side effects

- Cyto-histological diagnosis of small cell lung cancer, carcinoid, or mixed small-cell
/ non-small cell lung cancer;

- Patients with evaluable, not measurable disease only (non target lesions);

- Patients with symptomatic brain metastases or with leptomeningeal disease;

- History of prior malignancies, except for cured non melanoma skin cancer, curatively
treated in situ carcinoma of the cervix or other cancer curatively treated and with
no evidence of disease for at least five years;

- History of hypersensitivity reaction to polysorbate 80;

- Pregnant or lactating women (women of childbearing potential must use adequate

- Current peripheral neuropathy NCI grade > 2;

- Significant neurological or psychiatric disorders ;

- Participation in clinical trials with other experimental agents within 30 days of
study entry;

- Other serious concomitant illness of medical conditions:

1. Uncontrolled cardiovascular disease;

2. History of significant neurologic or psychiatric disorders including demential
or seizures;

3. Active infection requiring iv antibiotics;

4. Active ulcer, unstable diabetes mellitus or other contra-indication to

5. Any other condition which in the judgement of the investigator would place the
subject at undue risk or interfere with the study.

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

overall response rate assessed by RECIST criteria.

Outcome Time Frame:

before, during and at the end of treatment

Safety Issue:


Principal Investigator

Georges Paizis, MD

Investigator Role:

Study Director

Investigator Affiliation:



Italy: Ministry of Health

Study ID:




Start Date:

May 2005

Completion Date:

August 2008

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms